RAPID COMPLEMENT INHIBITION WITH THE C5 INHIBITOR CROVALIMAB: TIMING ANALYSIS USING ANIMAL MODEL AND COMPOSER TRIAL DATA

https://storage.unitedwebnetwork.com/files/1099/7cc33f7ebe962063eb1add33b3d603af.pdf
RAPID COMPLEMENT INHIBITION WITH THE C5 INHIBITOR CROVALIMAB: TIMING ANALYSIS USING ANIMAL MODEL AND COMPOSER TRIAL DATA
Rocio
Soldati
Cristian Brocchieri cristian.brocchieri@roche.com F. Hoffmann-La Roche Ltd. Hematology and Nephrology Rare Diseases Basel
Leigh Beveridge beveridl@gene.com Genentech, Inc. Product Development Hematology San Francisco, CA
Muriel Buri muriel.buri@roche.com F. Hoffmann-La Roche Ltd. Product Development (PD) Data Sciences (PDD) Basel
Niels Janssen niels.janssen@roche.com F. Hoffmann-La Roche Ltd. Pharmaceutical Sciences, pRED Basel
Patty Leon leon.patty@gene.com Genentech, Ltd PDH Rare Blood Disorders City: San Francisco, CA
Yoshinori Tsuboi yoshinori.tsuboi@businesspartner.roche.com Chugai Pharmaceutical Co. Research Division Tokyo
Simon Buatois simon.buatois@roche.com F. Hoffmann-La Roche Ltd. Pharmaceutical Sciences Basel